Adalimumab/etanercept/infliximab

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2012年 / 1432卷 / 1期
关键词：
D O I：
10.1007/s40278-012-0154-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [31] Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
    Skov, Lone
    Kragballe, Knud
    Dam, Tomas
    Poulsen, Johan Holk
    Obitz, Erik
    Gniadecki, Robert
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S61 - S61
  • [32] Frequency and Effectiveness of Dose Increase of Adalimumab, Etanercept, and Infliximab in Daily Clinical Practice
    Blom, M.
    Kievit, W.
    Kuper, H. H.
    Jansen, T. L.
    Visser, H.
    den Broeder, A. A.
    Brus, H. L. M.
    van de laar, M. A. F. J.
    van Riel, P. L. C. M.
    ARTHRITIS CARE & RESEARCH, 2010, 62 (09) : 1335 - 1341
  • [33] DOWN-TITRATION AND DISCONTINUATION OF INFLIXIMAB, ADALIMUMAB AND ETANERCEPT IN ESTABLISHED RHEUMATOID ARTHRITIS
    Lojo, L.
    Bonilla, G.
    Peiteado, D.
    Villalba, A.
    Plasencia, C.
    Nuno, L.
    Balsa, A.
    Martin-Mola, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 237 - 237
  • [34] Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
    Hebeisen, Monika
    Scherer, Almut
    Micheroli, Raphael
    Nissen, Michael J.
    Tamborrini, Giorgio
    Moller, Burkhard
    Zufferey, Pascal
    Exer, Pascale
    Ciurea, Adrian
    PLOS ONE, 2019, 14 (05):
  • [35] Adalimumab/Etanercept/Golimumab/Infliximab/Methotrexate/Pamidronic-acidPsoriasis and lack of efficacy
    Reactions Weekly, 2024, 2009 (1) : 28 - 28
  • [36] Dosing patterns and costs of adalimumab, etanercept, and infliximab among patients with rheumatoid arthritis
    Engel-Nitz, N. M.
    Huang, X.
    Globe, D.
    Baumgartner, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 260 - 260
  • [37] Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation
    McLeod, C.
    Bagust, A.
    Boland, A.
    Dagenais, P.
    Dickson, R.
    Dundar, Y.
    Hill, R. A.
    Jones, A.
    Mota, R. Mujica
    Walley, T.
    HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (28) : IX - +
  • [38] THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS
    Lawson, R. W.
    Heatley, R. M.
    Johnson, K., I
    Khandker, R. K.
    Singh, A.
    VALUE IN HEALTH, 2010, 13 (07) : A308 - A308
  • [39] Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
    Rodgers, M.
    Epstein, D.
    Bojke, L.
    Yang, H.
    Craig, D.
    Fonseca, T.
    Myers, L.
    Bruce, I.
    Chalmers, R.
    Bujkiewicz, S.
    Lai, M.
    Cooper, N.
    Abrams, K.
    Spiegelhalter, D.
    Sutton, A.
    Sculpher, M.
    Woolacott, N.
    HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (10) : 1 - +
  • [40] Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
    Gniadecki, R.
    Kragballe, K.
    Dam, T. N.
    Skov, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (05) : 1091 - 1096
12345